Drug intelligence / Profile preview

AR-712

Development stage: Preclinical
Lead developer: Aridis Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Inhalation

Overview

**AR-712** is an investigational inhaled, self-administered cocktail of two fully human IgG1 monoclonal antibodies being developed by Aridis Pharmaceuticals for mild-to-moderate COVID-19 in non-hospitalized patients. The antibodies bind conserved receptor-binding-domain regions of the SARS-CoV-2 spike glycoprotein and are intended to neutralize viral variants, with a proprietary formulation designed to protect the antibodies during nebulized delivery. The current Aridis program page identifies the cocktail components as AR-711 and AR-720. ([aridispharma.com](https://www.aridispharma.com/ar-712/))

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on AR-712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR-712.

Explore the full profile